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EVALUATION AND FOLLOW-UP OF PATIENTS WITH N1-3 
MO OR NXM1 PROSTATE CANCER IN PHASE III TRIALS
REGINALD HALL, PER OLOV HEDLUND, ROLF ACKERMANN, NICHOLAS BRUCHOVSKY, 
OTILIA DALESIO, FRANS DEBRUYNE, GERALD P. MURPHY, MAHESH K.B. PARMAR,
MICHELE PAVONE-MACALUSO, MIRJA RUUTU, a n d  PHILIP SMITH
ABSTRACT
Objectives. The aim of this discussion is to review the design and conduct of phase 111 trials in metastatic 
prostate cancer, to seek ways of improving their study design, accuracy, relevance to clinical practice, ac­
ceptability to patients, and ease of participation by clinicians. We also aim to try to set uniform definitions 
for the evaluation of the different endpoints used in clinical trials on metastasized prostate cancer. 
Methods. The work was started by correspondence between the participants in the group for the year before 
the consensus meeting. Two comprehensive questionnaires were circulated and the answers were distributed 
to all the members of the group. The statements were finalized during the consensus meeting.
Results. There were some differing opinions concerning the methods of evaluation of endpoints for follow- 
up, such as time to tumor progression and time to treatment failure. After the consensus conference, there 
were no major disagreements within the group.
Conclusions. The aim of phase 111 trials is to influence clinical management. To obtain a credible result they 
require a sound statistical basis with appropriate power and encompassing patients from small urologie practices 
as well as large or academic institutions. However, deviation from routine practice may affect the accrual rate, 
and the trial procedure should therefore be as similar as possible to routine management Trials inevitably involve 
extra work and cost. Both should be kept to a minimum to encourage participation and hasten a timely conclusion. 
It is mandatory to create uniform ways of designing and evaluating clinical trials in prostate cancer, u r o l o g y  49 
(Suppl 4A): 39-45, 1997. ©1997 by Elsevier Science Inc. All rights reserved.
T he aim of this discussion is to review the de­
sign and conduct of Phase III trials in meta­
static prostate cancer for the purpose of seeking
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ways of improving their study design, accuracy, 
relevance to clinical practice, acceptability to pa­
tients, and ease of participation by clinicians.
The benefit sought from a new treatment should 
be defined at the outset of a trial. Benefit may be an 
increase in survival, time to progression, or quality of 
life, or a decrease in the toxicity or cost of treatment.
The purpose of Phase III trials in metastatic 
prostate cancer is to compare the efficacy of 2 or 
more forms of treatment or patient management 
in patients who have received no previous treat­
ment for their cancer. Comparison of the treat­
ment’s impact on survival is the usual endpoint, 
but other endpoints, such as disease progression, 
may be appropriate. Measurement of response of 
evaluable disease parameters is not usually a sub­
ject of study for phase III trials. Demonstration 
and measurement of response to treatment is the 
role of phase II studies. The planning of phase III 
trials is discussed elsewhere, but it is important 
that study design should include, from the outset, 
the status of the patients, the extent of disease, and
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stratification for prognostic factors of proven sig­
nificance. L~3 The planned size of the trial will need 
to take into consideration the magnitude of the 
benefit sought, the number and time scale of ex­
pected events, and the anticipated time to accrue 
the necessary number of patients.4,5
A clear understanding of the information required 
to answer the question posed by a trial is essential 
when the study is being designed. The parameters 
measured and recorded in phase III trials are those 
needed to determine the chosen endpoint. The fre­
quency of their assessment reflects the expected tim­
ing of critical events and the expected duration of 
survival. These are not necessarily the same as 
needed for routine clinical management.
The aim of phase III trials is to influence clinical 
management. To obtain a credible result, phase III 
trials require a sound statistical basis with appropri­
ate power encompassing patients from small urol­
ogie practices as well as large or academic institu­
tions. However, deviation from routine practice may 
affect the accrual rate and should therefore be as 
similar as possible to routine management. Trials in­
evitably involve extra work and cost. Both should be 
kept to a minimum to encourage participation and 
hasten a timely conclusion.
The treatment of metastatic prostate cancer is 
palliative for the large majority of patients, and as 
a consequence, time spent without symptoms 
from the disease or side effects of treatment is im­
portant. Asymptomatic patients with distant mé­
tastasés do not require hormonal treatment for 
symptomatic progression for 9 to 12 months.6 For 
most patients with symptomatic métastasés, pro­
gression after hormone treatment tends to occur 
after 12 to 18 months, but for those with “minimal 
disease” it may be 3 years or longer.7'8 In those 
with lymph node, but no distant, métastasés, pro­
gression may not occur for several years, and me­
dian survival is considerably longer than 5 years.9 
The inevitable delay that this causes in obtaining 
the result of a trial has led to a search for alter­
native, shorter, surrogate endpoints.
Tumor progression, treatment failure, and rising 
serum prostate-specific antigen (PSA) level have all 
assumed increasing importance in phase III trials. 
The time from entry into study to the occurrence of
1 or more of these events has been used as a basis 
for analysis. A rise in PSA causes no physical symp­
toms but may cause anxiety. Similarly, the devel­
opment of new hot spots on the bone scan or other 
radiologic evidence of disease progression is of rel­
atively little concern to the patient unless associated 
with pain or other symptoms. Time to treatment fail­
ure is probably less important to the patient than 
symptomatic disease progression.
Each of these endpoints provides data that in­
creases our understanding of prostate cancer and
helps to refine patterns of care. They are therefore 
useful endpoints for study in phase III trials. How­
ever, the overriding desire of the patient is in­
creased survival and a reduced likelihood of dying 
from prostate cancer.
ENDPOINTS
Overall survival is the most robust endpoint for 
phase III study10 and has the greatest impact for 
the patient. It is the most accurate, objective, and 
easiest to measure. Quality of life, freedom from 
symptoms or unwanted side effects of treatment, 
and absence of overt disease progression are all 
important to patients with prostate cancer, but the 
eventual aim of treating prostate cancer is to pre­
vent death from this disease and its treatment. The
*
cause of death (disease-specific survival) is there­
fore relevant.
Duration of survival is not just determined by 
the first treatment, but is made up of several pe­
riods of disease control achieved by different treat­
ments. At present, second- and third-line treat­
ment (after hormone relapse) contribute relatively 
little to overall survival, but may become more im­
portant in the future when effective, nonhormonal 
treatments become available. Thus the duration of 
benefit from individual treatments may be impor­
tant to measure. For this, 2 different time periods 
can be used: time to tumor progression (TTP)1,10 
or time to treatment failure (TTTF).11
For asymptomatic patients, delayed treatment is 
still an option. Time before commencement of 
treatment needs to be measured in trials that in­
corporate this management concept.6
SURVIVAL
O v e r a l l  S u r v iv a l
Overall survival is very relevant because most 
men with metastatic prostate cancer will die 
within the time scale of the study; the majority of 
prostate cancer. Mean age at diagnosis has been 
more than 70 years, but appears to be falling and 
comorbidity has less influence on outcome.
The pattern of care provided by health services 
varies between countries. Long-term follow-up by 
the institution that initiated treatment is not al­
ways possible and the precise date of death of pa­
tients may not be known. However, many coun­
tries now have national registration of mortality 
and participants in phase III trials should be re­
quired to obtain confirmation of the date of death 
from such registries if necessary.
An overall survival benefit should only be con­
sidered to be significant clinically if accompanied 
by an equivalent improvement in disease-specific 
survival.
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D i s e a s e -S p e c i f i c  S u r v i v a l  (D S S )
( C a u s e -S p e c i f i c  S u r v i v a l )
In principle this is the most desirable endpoint 
but its value is undermined by the difficulty ex­
perienced in its definition.
For many men with prostate cancer, it is evident 
that this disease has been the cause of their death, 
but for others the exact cause of death is uncertain. 
Death certificates are not always reliable. Patients 
with clinical signs of progressive cancer immediately 
prior to death should usually be counted as cause- 
specific deaths. Agonal events, such as pulmonary 
embolism, major hemorrhage, pneumonia, or sepsis, 
occurring in a patient who is severely ill in the final 
stages of progressing prostate cancer, should not be 
identified as the cause of death. These patients 
should be considered to have died of prostate cancer. 
However, it should be remembered that even when 
a patient has progressive cancer, death may be due 
to a sudden and entirely unrelated cause, such as 
cardiovascular disease. Elevated PSA alone, in the 
absence of symptoms or signs of disease progression, 
is not sufficient to indicate prostate cancer as the 
cause of death.
It has been suggested that the terms disease-spe­
cific survival or cause-specific survival should in­
clude only those deaths that are directly attribut­
able to prostate cancer, and not include deaths due 
to treatment. This definition is rejected. Death due 
to treatment toxicity, and therefore a consequence 
of the disease, should also be considered as death 
due to the cancer for the purpose of calculating 
disease-specific survival.
The cause of death of a patient in a clinical trial 
has to be decided by the clinical coordinator, after 
appropriate inquiry to answer the question “was 
the patient’s death directly, or indirectly, a result 
of prostate cancer or its treatment?” In addition, it 
is recommended that phase III trial organization 
should include an independent “Cause of Death 
Committee” if DSS is a major endpoint,
D i s e a s e -F r e e  S u r v i v a l  ( D F S )
Complete pathological remission of metastatic 
prostate cancer is rare. Thus “disease-free survival” 
is not relevant as an endpoint for phase III study 
in this disease.
R e l a t i v e  S u r v i v a l
The endpoint of “relative survival” cannot be ap­
plied to phase III trials because survival should only 
be compared within the randomization of the trial.
L e t h a l  A d v e r s e  E v e n t s
Lethal adverse events following treatment 
should be uncommon in phase III trials, but all 
treatment-related deaths should be identified and
reported as a subgroup in survival analyses. They 
should also be included in DSS calculations.
Since adverse events may be difficult to identify, 
all events that cannot be related to an expected 
progression of the malignant disease should be re­
ported and registered, together with evidence to 
justify the conclusion. The detailed reporting of 
adverse events as currently required for registra­
tion studies of new drugs is burdensome. For non- 
serious adverse events, it is not necessary for most 
phase HI trials. For serious adverse events, a sim­
pler format of recording these events is required 
for future phase III trials.
DISEASE PROGRESSION
Two types of disease progression, “clinical” and 
“biochemical,” are recognized for the purposes of 
phase III trials.12,13
C l i n i c a l  P r o g r e s s i o n
The progression of prostate cancer takes many 
forms, is often difficult to document until far ad­
vanced, and may not be evident until late in the 
patient’s disease pathway. In a trial, objective evi­
dence of disease progression is usually considered 
desirable.13
The following events are considered to be of par­
ticular importance for patients with progressive 
prostate cancer, and, in a phase III trial, are to be 
regarded as evidence of clinical progression: pain, 
anemia, symptoms or signs of upper tract obstruc­
tion, urinary symptoms, malignant lymphadenop- 
athy, lymphoedema, symptoms or signs of spinal 
cord compression, pathological fracture, or de­
cline in performance status due to prostate cancer.
It is recognized that anemia may be treatment-re­
lated rather than signifying progressive disease; pro­
longed androgen deprivation may result in a drop in 
hemoglobin of 2 to 3 g/L. In judging disease pro­
gression, it is important to ensure that the above 
factors are related to the malignancy rather than 
other intercurrent disease or treatment toxicity.
Imaging at regular, predetermined intervals has 
been used in many previous trials. This experience 
has revealed that the interpretation of asympto­
matic new hot spots on bone scans, with or with­
out x-rays, can be difficult,14 and asymptomatic 
lung or lymph node métastasés seldom warrant 
treatment. Bone scan is mandatory at entry to 
phase III trials and is commonly used to evaluate 
progression. Chest x-ray, computed tomography 
(CT) or magnetic resonance (MR) scans are re­
served for the investigation of symptoms. They 
will have cost implications if required specifically 
for a clinical trial. Although they provide useful 
evidence to support the diagnosis of clinical pro­
gression, it is recommended that the planned use
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of these investigations at regular intervals is not 
essential for phase III trials.1 This is not to say that 
disease progression is unimportant and should not 
be recognized in trial design. Because the diagnosis 
of tumor progression depends on subjective fac­
tors and clinical acumen as well as objective mea­
surement, the definition of “clinical progression” 
cannot be precise. The following definition of clin­
ical progression is recommended: new symptoms 
or signs, or worsening of those already existing, 
clearly attributable to prostate cancer.
B i o c h e m i c a l  P r o g r e s s i o n
Several biochemical serum parameters have been 
shown to have prognostic significance when mea­
sured at the time of diagnosis or entry into a trial 
and may also indicate disease progression before 
this is evident clinically. Those of prognostic sig­
nificance need to be measured at entry into the 
trial, but only require repetition during follow-up 
if they also act as indicators of progression.
It is agreed that prostate-specific antigen (PSA) 
is the most reliable measure of disease activity cur­
rently available and should be measured at regular 
intervals.15-18 A rise in PSA has been shown to pre­
date radiologic and symptomatic disease progres­
sion by many months and is generally accepted to 
be the most reliable first indication of treatment 
failure in the majority of patients.12,17,18 It is 
agreed, therefore, that "biochemical progression” 
based on rising PSA is an endpoint of considerable 
interest. Furthermore, an association between PSA 
“response” and survival is becoming apparent,15,19 
although long-term data are as yet insufficient to 
support the use of serum PSA as a surrogate end­
point of proven value.
It should be recognized that PSA expression is 
hormone-dependent, and a considerable decrease 
may not necessarily represent significant disease 
regression.20 Furthermore, some antitumor effects 
from nonhormonal treatment may not lead to a 
decrease in PSA levels.21 It should also be remem­
bered that PSA almost certainly will be replaced 
by a better biochemical marker in the future.
In patients with advanced prostate cancer, a rise 
in serum creatinine usually indicates ureteric ob­
struction; elevated alkaline phosphatase suggests 
either progressive bone or liver metastases; and a 
fall in hemoglobin probably, but not necessarily, 
indicates bone marrow involvement. Each of these 
biochemical or hematologic measurements con­
tributes to the diagnosis of clinical progression 
and should be measured during follow-up, but as 
individual parameters, they do not amount to 
“biochemical progression.” A fall in PSA to normal 
or near-normal following protocol treatment is a 
significant prognostic factor for the duration of 
survival.15 It may therefore be used to stratify pa­
tients as a determinant of intermittent treatment 
or randomization to a second treatment. Fall in 
PSA cannot be used to stratify for analysis of out­
come. In the future, prostate-specific membrane 
antigen (PSMA), neuroendocrine markers, radio- 
labeled antibodies, and other methodologies may 
provide additional or alternative indicators of pro­
gression. For the foreseeable future it is recom­
mended that biochemical progression should be 
defined as a sustained and continuing rise in se­
rum PSA. The percentage change in PSA or the 
threshold PSA level will need to be defined for in­
dividual trials. In some patients a fall in PSA is not 
observed. For these a “no change” category may 
need to be defined.
T im e  t o  P r o g r e s s i o n  (T T P )
Progression, clinical, biochemical, or both, is a 
useful endpoint in phase III trial design. The time at 
which this event occurs therefore requires defini­
tion. As evidence of progression, it is the time at 
which PSA rises (after falling to a nadir, or remaining 
unchanged after treatment) that is relevant. It is pro­
posed that time to tumor progression be defined as 
the time at which clinical or biochemical progression 
is first observed as defined above.
Tim e t o  T r e a t m e n t  F a i l u r e  (T T T F )
This endpoint is similar to TTP but also in­
cludes, the “failure” of treatment due to toxicity as 
well as treatment failure manifest by cancer pro­
gression.11 For the comparison of treatments that 
can be stopped, it has greater practical relevance 
than TTP.
TTTF differs from TTP in that prostate cancer 
may remain unchanged, or even improved for a 
considerable time when treatment is withdrawn. 
As a consequence, TTTF will usually be shorter 
than TTP when applied to the comparison of 2 
different treatments.
TTTF is defined as the time from entry into the 
trial to clinical or biochemical progression or with­
drawal of treatment because of treatment toxicity, 
or death, whichever is the shortest.
S y m p t o m - F r e e  I n t e r v a l
The management of some patients by careful 
monitoring and delayed hormone treatment or by 
intermittent hormone therapy creates another 
clinical scenario that requires consideration in 
phase III trial design. This concept differs from 
immediate, continuous treatment because it in­
cludes periods of time when the patient receives 
no treatment and is asymptomatic.22 These periods 
comprise freedom from the morbidity of prostate 
cancer and may be single (before delayed therapy) 
or multiple (within intermittent therapy). They
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are important because they address the problem of 
disease morbidity and quality of life.
If the symptom-free interval is to be used as an 
endpoint, it will be important to avoid bias from 
the tendency to treat the patient sooner if an “ef­
fective” treatment is still available compared 
with the inevitable reluctance to investigate 
symptoms of possible progression if further 
treatment choice is limited. Whether treatment 
is delayed initially or given intermittently, it is 
the total time free of symptoms as a proportion 
of overall duration of survival that is relevant. 
The symptom-free interval is defined as the total 
period of time, within the trial protocol, during 
which the patient has no symptoms attributable 
to his prostate cancer.
FOLLOW-UP
In v e s t i g a t i o n s
The investigations to be performed and re­
corded during the follow-up of patients in phase 
III trials are those required to document the fol­
lowing: compliance with treatment, toxicity, and 
any adverse events related to treatment, symp­
toms of prostate cancer, progression of prostate 
cancer (clinical or biochemical), and death or 
survival.
Requirements for phase III trial follow-up may 
not be the same as those for clinical practice, 
particularly as the latter appears to differ accord­
ing to institution or country. There is therefore 
a need to agree on a minimum data set for fol- 
low-up that should be required for all phase III 
trials. These comprise quality of life (including 
urinary symptoms), pain due to prostate cancer, 
performance status (change due to prostate can­
cer), clinical examination, serum PSA, serum 
creatinine, hemoglobin, alkaline phosphatase, 
bone scan or other imaging techniques as indi­
cated for assessment of progression, and sur­
vival. Other blood tests or imaging will be em­
ployed as indicated clinically, but are not to be 
included in the minimum data set.
F r e q u e n c y  o f  F o l l o w -U p
To facilitate patient recruitment and clinician 
participation, and to minimize unnecessary work 
and cost, follow-up visits in phase III trials should 
coincide with clinical management whenever pos­
sible. Currently, these tend to be at 3-monthly in­
tervals for the first year, progressing to 6-monthly 
and possibly annually. However, this pattern of 
follow-up visits may not be the most appropriate 
for the likely time scale of important events. If 
TTTF or TTP are study endpoints, frequent eval­
uation is necessary during the first year to ensure 
treatment compliance and detection of toxicity.
Thereafter, the interval between follow-up visits 
should be designed according to the expected du­
ration of survival in a particular study and the an­
ticipated timing of critical events, such as tumor 
progression. For trials evaluating intermittent 
therapy more frequent visits will probably be nec­
essary. The data to be collected on these additional 
visits should be limited to that upon which treat­
ment decisions are based, namely, PSA (or another 
marker) and quality of life questionnaire. What­
ever pattern of follow-up is employed, it is essen­
tial that the frequency of visits is the same in both 
or all arms of the trial.
It has been proposed that, for trial purposes, data 
sheets need only be completed at annual intervals to 
record data concerning critical events retrospectively, 
but leaving the frequency of follow-up to individual 
preference.6 The advantage of this trial design is its 
simplicity and savings in data management costs. 
Such trials minimize the amount of work required 
specifically for the trial and, in their simplest form, 
could amount to no more than the recording of the 
date of death from national cancer registries. The 
main disadvantage of this trial design is that the re­
corded time to critical events depends upon the fre­
quency of the follow-up visits and excessive variation 
in this will undermine the quality or strength of the 
endpoint in question. Reliance solely on annual fol­
low-up is recommended only for trials that address 
the single endpoint of overall survival, with other 
endpoints being relatively unimportant. This will 
rarely be the case for patients with metastatic disease.
R e t r o s p e c t i v e  S e q u e n t i a l  M e t h o d
Although trial protocols encourage the definition 
of clear endpoints and the date of occurrence of cer­
tain events, experience teaches that such precision 
is often lacking in everyday practice. Typically, the 
clinician suspects that disease progression is occur­
ring, but the definite diagnosis of disease progression 
can only be made after several visits, over a consid­
erable period of time, or when the results of a num­
ber of investigations become available* The defini­
tion of TTP or TTTF has been a cause of 
considerable difficulty in many previous trials. In­
evitably, the diagnosis of treatment failure or disease 
progression is made retrospectively and usually in a 
sequential way. It is therefore recommended that the 
retrospective sequential method be used in future 
phase III trial designs, whereby the first signs of de­
terioration in any parameter are noted and the find­
ing is followed consecutively (at the predetermined 
follow-up intervals) for confirmation of progressive 
disease or for cancellation, if tumor relapse is not 
confirmed. The first date of suspicion of progression 
(the date of first rise in PSA, the onset of pain, or 
the first fall in hemoglobin) is eventually counted as 
the time point for TTP or TTTF.
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T r i a l  I n v e s t i g a t o r
In some countries, clinical nurse specialists are 
increasingly performing medical tasks that may in­
clude some required for clinical trials. In addition, 
“shared care” programs have encouraged family 
general practitioners to play a greater role in man­
aging patients with prostate cancer. These patterns 
of care may be appropriate for clinical manage­
ment, but patients in randomized clinical trials 
should be followed-up under the direct supervi­
sion of the responsible specialist physician.
QUALITY OF LIFE
Quality of life (QOL) evaluation is complex and 
both questionnaires and their analysis may appear 
to take a disproportionate amount of time. For this 
reason, they may not be considered to be necessary 
for all phase III trials. For phase III trials in which 
TTP or survival are main endpoints, QOL mea­
surement may be necessary for a selected propor­
tion of the trial population only. Nonetheless, if 
QOL is to be studied, this decision should be made 
when designing the trial and arrangements made 
for QOL assessment in such a manner as to ensure 
that it is recorded at the same time as all other 
critical parameters. Quality of life evaluation is a 
relatively new field of research and its contribution 
to clinical decision making and disease manage­
ment has yet to be established. Since in metastatic 
prostate cancer treatment offers palliation rather 
than cure, the quality of the remaining life is of 
considerable importance.
STATISTICAL CONSIDERATIONS
The objectives of a phase III trial should be 
achievable and applicable to clinical practice. 
Analysis of the results of phase III trials is a spe­
cialist statistical issue, but one that requires clini­
cal input. The statistical principles for the analysis 
of phase III trials have been well defined and there 
is a considerable body of international expertise to 
advise on the design of future trials.4,5,23"26
Avoidance of bias by the use of proper random­
ization methods and analysis on the basis of “in­
tention to treat” is fundamental. Trial design based 
on an awareness of relevant prognostic factors and 
appropriate stratification is also essential. Evalua­
tion of outcomes is a statistical exercise, but “clin­
ical significance” is at least as important as “statis­
tical significance” if the results of phase III trials 
are to influence future clinical practice. Cancers 
differ in their biological behavior, their response 
to treatment, and the duration of their overall “pa­
tient pathway.” Wide variation is often seen in 
prostate cancer, which means that all phase III tri­
als will not be identical- Rather, the choice of end­
point, the pattern of follow-up, and the treatment
will depend on the category and extent of prostate
cancer to be studied.
For the immediate future, modifications of cur­
rently available treatments may improve survival, 
but differences between treatments will probably 
be fairly small. A meta-analysis of trials of maxi­
mum androgen blockade suggested nonsignificant 
differences of only a few months27 and it is clear 
that some colleagues consider such small differ­
ences to be of little practical importance. To assess 
mortality differences of only moderate size, studies 
of thousands of patients are necessary to avoid the
play of chance.26
To ensure that trials have clinical significance as 
well as statistical validity, participants should de­
cide at the outset the magnitude of benefit (in­
crease in survival, TTTF, time free of symptoms) 
that would lead to the routine use of the new treat­
ment. The statistical design and the number of pa­
tients will be determined by these clinical consid­
erations. If the desired benefit is larger than the 
benefit that can be expected on the basis of epi­
demiologic or pharmacologic data, the study 
should not be started.
The lack of curative treatment has led to a 
greater emphasis on quality of life, freedom from 
symptoms, and freedom from treatment side ef­
fects, based on the assumption that survival will 
be the same for the treatments compared, that is, 
the “equivalence” of survival. For example, if a 
new treatment is found to be less toxic, the trial 
needs to show reliably that the survival obtained 
is not compromized compared with the standard 
treatment. In practice, proof of absolute equiv­
alence is not feasible. Thus, if phase III trials in 
future are to be of this nature, there is a need to 
define a limit to the difference in survival that is 
acceptable as “equivalent.” For example, assum­
ing a median survival of 36 months for M l pa­
tients, would a new treatment be considered 
beneficial if symptoms and side effects are re­
duced but median survival is also reduced? If so, 
by how much? Three, 6, 9, or 12 months? In­
deed, is any reduction in survival acceptable? 
Conversely, what increase in survival is consid­
ered clinically significant for a new treatment? 
Does the answer depend upon treatment toxicity 
or the cost of the treatment in question? Answers 
to these questions will undoubtedly be conten­
tious, but if controversy is to be avoided when 
the results of individual trials or meta-analyses 
are published, consensus guidelines should be 
agreed to as a basis for future trials.
For patients with a medium or good prognosis 
and expected median survival of 3 years or more, 
a decrease in survival of up to 6 months, but no 
more, is suggested as an acceptable basis for the 
statistical definition of equivalence. A 6-month
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“trade-off* is also suggested as the maximum ac­
ceptable, even when longer survival is expected. 
For poor prognosis patients whose median sur­
vival is only 18 months, a possible reduction of up 
to 3 months might be accepted by patients, de­
pending on the advantages to be gained from the 
new treatment.
Clinicians are uncomfortable with the idea that 
any new treatment that may reduce survival could 
be described as “acceptable.” Nonetheless, as al­
ready recognized, proof of absolute equivalence is 
not feasible. Thus, for clinical trial purposes, def­
initions of equivalence will be essential to safe­
guard patients and ensure that the possibility of 
trial investigators accepting a large survival dis­
crepancy is excluded by the trial design. The need 
for such definitions is a reflection of the palliative 
nature of current treatments for metastatic pros­
tate cancer.
In the future, new treatments will become avail­
able that offer cure rather than palliation. These 
may replace or be combined with hormone treat­
ment. This consensus document seeks to set 
guidelines that will be relevant to such future sit­
uations. Overall survival will be the main endpoint 
for these future phase III trials.
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